PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of information unless a contains a valid OMB control number.

Substitute for form 1457

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

 Sheet
 1
 of
 22
 Attorney Docket Number
 2578-4123.2US

	_	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant			
Examiner Initials *	No.	Number - Kind Code ² ((f known) MM-DD-YYYY	101 00 2000		Can	Cred Document	Cased Document	Passages or Relevant Pigures Appear
MM		4,487,829	12/11/84	Sharp et al.	/			
<u> </u>		4,517,686	05/21/85	Ruoslahti et al.				
		4,578,079	03/25/86	Ruoslahti et al.				
		4,589,881	05/20/86	Pierschbacher et al.				
1	i i	4,593,002	06/03/86	Dulbecco				
	Ĭ	4,792,525	12/20/88	Ruoslahti et al.				
1		4,797,368	01/10/89	Carter et al.				
	Ì	4,956,281	09/11/90	Wallner et al.				
		5,024,939	06/18/91	Gorman				
	1	5,096,815	03/17/92	Ladner et al.	Y			
	1	5,166,320	11/24/92	Wu et al.	\wedge			
		5,198,346	03/30/93	Ladner et al.				
	1	5,204,445	04/20/93	Plow et al.	/			
	1	5,223,394	06/29/93	Wallner				
	1	5,223,409	06/29/93	Ladner et al.				
	1	5,240,846	08/31/93	Collins et al.				
\neg	1	5,246,921	09/21/93	Reddy et al.	1. /			
		5,332,567	07/26/94	Goldenberg				
	1	5,349,053	09/20/94	Landolfi	1/			
m M	1	5,403,484	04/04/95	Ladner et al.	1/			

			FOR	EIGN PATENT	T DOCUMENTS		
			Foreign Patent Document			Pages, Columns, Lines,	
	miner tials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
M	M		EP 259212	08/11/87	Transgene S.A.		
			WO 91/00360	01/10/91	Medarex, Inc.		
			WO 91/05871	05/02/91	Medarex, Inc.		
			WO 91/05805	05/02/91	Trustees of Dartmouth College		
			WO 92/02553	02/20/92	Delta Bi-Otechnology Limited		
M	M		WO 92/13081	08/06/92	British Technology Group PLC		

Examiner Signature MMMMC	Date Considered	5/10/05
--------------------------	--------------------	---------

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unites; it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 09/348,354 INFORMATION DISCLOSURE **Application Number** July 7, 1999 Filing Date STATEMENT BY APPLICANT Havenga et al. First Named Inventor Group Art Unit 1636 (use as many sheets as necessary) **Examiner Name** M. Marvich 2578-4123.2US of 22 Sheet Attorney Docket Number

	·	B	U.S. PATENT D	Name of Patentee or Applicant of	T
Examiner	Cine	Document Number	Publication Date	Cited Document	Pages, Columns, Lines, Where Relevant
Initials *	No.	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
MW		5,436,146	07/25/95	Shenk et al.	
1		5,443,953	08/22/95	Hansen et al.	
\neg		5,474,935	12/12/95	Chatterjee et al.	
		5,521,291	05/28/96	Curiel et al.	
		5,534,423	07/09/96	Plasson et al.	
		5,543,328	08/06/96	Mcclelland et al.	
1		5,547,932	08/20/96	Curiel et al.	7
		5,552,311	09/03/96	Sorscher et al.	
		5,559,099	09/24/96	Wickham et al.	
		5,571,698	11/05/96	Ladner et al.	
		5,622,699	04/22/97	Ruoslahti et al.	
		5,712,136	01/27/98	Wickham et al.	
		5,731,190	03/24/98	Wickham et al.	
		5,756,086	05/26/98	Mcclelland et al.	
		5,770,442	06/23/98	Wickham et al.	
		5,837,511	11/17/98	Flack-Pedersen et al.	
		5,846,782	12/08/98	Wickham et al.	
	1.	5,849,561	12/15/98	Falck-Pedersen	1
		5,856,152	01/05/99	Wilson et al.	17
MIM	ĺ	5,871,727	02/16/99	Curiel	17

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	l	Foreign Patent Document			Pages, Columns, Lines,	-				
	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known) Publication D MM-DD-YY		Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶				
W	M		WO 93/03769	03/04/93	U.S. Dept. of Health and Human Services					
1			WO 93/06223	04/01/93	Centre National De La Recherche Scientifique					
			WO 93/07282	04/15/93	Boehringer Ingelheim International GMBA					
			WO 93/07283	04/15/93	Boehringer Ingelheim International GMBA					
			WO 94/08026	04/14/94	Rhone-Poulenc Rorer S.A.					
n	1m		WO 94/10323 -	05/11/94	Imperial Cancer Research Technology Limited					

Examiner Signature	mmanich	Date Considered	5/10/05
		· · · · · · · · · · · · · · · · · · ·	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
INFO	RMATIO	N DI	SCLOSURE	Application Number	09/348,354		
STATEMENT BY APPLICANT				Filing Date	July 7, 1999		
BIAI			ILLICANI	First Named Inventor	Havenga et al.		
				Group Art Unit	1636		
(use as many sheets as necessary)				Examiner Name	M. Marvich		
Sheet	3	of	22	Attorney Docket Number	2578-4123.2US		

			U.S. PATENT D	OCUMENTS	
		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Examiner Initials *	No.	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
YMMA_		5,871,982	02/16/99	Wilson et al.	
****		5,877,011	03/02/99	Armentano et al.	
		5,922,315	07/13/99	Roy	
- 1		5,994,128	11/30/99	Fallaux et al.	
	1	6,033,908	03/07/00	Bout et al.	
	1	6,057,155	05/02/00	Wickham et al.	X
	1	6,100,086	08/08/00	Kaplan et al.	
	1	6,127,525	10/03/00	Crystal et al.	
		6,287,857	09/11/01	O'riordan et al.	
		6,306,652	10/23/01	Fallaux et al.	
		6,486,133	11/26/02	Herlyn et al.	
		6,492,169	12/10/02	Vogels et al.	
MM		6,669,942	12/30/03	Perricaudet et al.	
 	<u> </u>				
	1				
			<u> </u>		· · · · · · · · · · · · · · · · · · ·
	İ	1	1	l	l

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*		Foreign Patent Document			Pages, Columns, Lines,						
	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T¢.					
MM		WO 94/11506	05/26/94	Arch Development Corporation							
NAM		WO 94/15644	07/21/94	Imperial Cancer Research Technology Limited							
MN		WO 94/17832	08/18/94	The Scripps Research Institute							
MM		WO 94/24299 .	10/27/94	Boehringer Ingelheim International GMBA							
WIN		WO 94/26915	11/24/94	The Regents of the University of Michigan							
ww		WO 95/05201	02/23/95	Genetic Therapy, Inc.							

Examiner Signature	MMunich	Date Considered	5/10/05	
	1101100010			

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 09/348,354 INFORMATION DISCLOSURE Application Number July 7, 1999 STATEMENT BY APPLICANT First Named Inventor Havenga et al. Group Art Unit 1636 (use as many sheets as necessary) **Examiner Name** M. Marvich 2578-4123.2US Attorney Docket Number

			U.S. PATENT D	OCUMENTS	
	~	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Examiner Initials *	Cite No. ¹	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
			ļ		
				ļ	
					
<u> </u>					
				ļ	
				 	
					
					
		 			
-	 	 			
					
-	1				
	1	<u> </u>		<u> </u>	
					

	FOREIGN PATENT DOCUMENTS										
		Foreign Patent Document			Pages, Columns, Lines,						
Examiner Initials*	Cite 'No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶					
MM		WO 95/06745	03/09/95	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.U.							
Mm		WO 95/14785	06/01/95	Rhone-Poulenc Rorer S.A.							
mm		WO 95/16037	06/15/95	Menarini Ricerche Sud S.p.A.							
mm		WO 95/21259	08/10/95	U.S. Dept. of Health and Human Services							
MM		WO 95/26412	10/05/95	The UAB Research Foundation							
mm		WO 95/27071	10/12/95	Board of Regents, The University of Texas System							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspro.gov or MPEP 901.04.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 09/348,354 INFORMATION DISCLOSURE **Application Number** Filing Date July 7, 1999 STATEMENT BY APPLICANT Fust Named Inventor Havenga et al. Group Art Unit 1636 (use as many sheets as necessary) **Examiner Name** M. Marvich 2578-4123.2US Attorney Docket Number

			U.S. PATENT D	OCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
			<u> </u>		
	ļ				
	ļ				
	-				
	 			 	
	 				
	 	-	 		
	 				
	 				
					W-17
		<u> </u>			
	l	1			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*		Foreign Patent Document			Pages, Columns, Lines,			
	Cite No. Country Code ² - Number ⁴ - Kind Code ² (if Incom)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶			
MM		WO 95/31187	11/23/95	McMaster University				
MAMA		WO 95/31566	11/23/95	Viagene, Incorporated				
WALAA		WO 96/00326	01/04/96	Reinert, Gary, L., Sr.				
WW		WO 96/00790	01/11/96	Rhone-Poulenc Rorer S.A.				
WW		WO 96/07739	03/14/96	Neurocrine Biosciences, Incorporated				
MM		WO 96/10087	04/04/96	Rhone-Poulenc Rorer S.A.				

Examiner Signature MMMMMM	Date Considered	5710/05
---------------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known 09/348,354 INFORMATION DISCLOSURE Application Number July 7, 1999 STATEMENT BY APPLICANT First Named Inventor Havenga et al. 1636 Group Art Unit (use as many sheets as necessary) **Examiner Name** M. Marvich 2578-4123.2US

Attorney Docket Number

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant			
Initials *	No.1	Number - Kind Code ² (if known)	MIM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear			
	ļ	ļ						
	-							
	-							
·	+	 						
·	 	 						
								
_								
	<u> </u>	<u> </u>	ļ <u></u>					
								
-	 	<u> </u>						
	 	 						
	+							
	 							
	 	 	<u> </u>					

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	l _	Foreign Patent Document			Pages, Columns, Lines,			
	Cite No. 1 Country Code ³ - Number ⁴ - Kind (if Instant)	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date M24-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear			
MM		WO 96/12030	04/25/96	Rhone-Poulenc Rorer S.A.	\mathcal{K}			
Was		WO 96/13598	05/09/96	The Trustees of the University of Pennsylvania				
MM		WO 96/13597	05/09/96	The Trustees of the University of Pennsylvania				
Win		WO 96/14837	05/23/96	Genetic Therapy, Inc.				
MIN		.WO 96/17073	06/06/96	Takara Shuzo Co., LTD.				
10 -		WO 96/ 18740	06/20/96	Rhone-Poulenc Rorer S.A.				

Examiner Signature	Mr Mars : A	Date Considered	5710/08	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless à contains a valid CMB control number.

Substitute	for form 1449 A/PT (0		1	Complete if Known	•
INFO	RMATIO	N DI	SCLOSURE	Application Number	09/348,354	
STATEMENT BY APPLICANT				Filing Date	July 7, 1999	
DIM	STATEMENT DE ATTRICANT		First Named Inventor	Havenga et al.		
				Group Art Unit	1636	
(use as many sheets as necessary)		Examiner Name	M. Marvich			
Sheet	7	of	22	Attorney Docket Number	2578-4123.2US	

			U.S. PATENT D		
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Initials *	No.¹	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
	ļ		i		
	†			†	

,		FOR	EIGN PATEN	T DOCUMENTS		
Examiner Initials*		Foreign Patent Document			Pages, Columns, Lines,	
	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if Insum)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T
MM		WO 96/24453	08/15/96	Withers, Graham, Rex	1	,
mm		WO 96/26281	08/29/96	Genvec, Inc. Cornell Research Foundation, Inc.		
MW		WO 96/35798	11/14/96	Introgene B.V.		
MM		WO 97/00326	01/03/97	Introgene B.V.	$X \perp$	
MAM		WO 97/12986	04/10/97	Cornell Research Foundation, Inc.		
MM		WO 97/20575	06/12/97	The University of Alabama at Birmingham Research Foundation		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is contains a variet OMB control combe-

		7122 02 1 14	# - G # 1000 1775 10	o persons are required to respond to a con-	CONTRACTOR DESCRIPTION OF STREET OF	ND COLLEGE HEREDS
Substitute fi	or form 1449A/PT	0			Complete if Known	
INFORMATION DISCLOSURE				Application Number	09/348,354	
STATEMENT BY APPLICANT		Filing Date	July 7, 1999			
V		~		First Named Inventor	Havenga et al.	
				Group Art Unit	1636	
(use as many sheets as necessary)			necessary)	Examiner Name	M. Marvich	
Sheet	8	of	22	Attorney Docket Number	2578-4123.2US	

-			U.S. PATENT D	OCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
britishs *	No.1	Number - Kind Code ² ((f Intown)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	-	 			
	-		 		
			 		
	 	ļ	 		
·					
	ļ		<u> </u>		
	-				
-	 		 	 	
	 	 	 		

		FOR	EIGN PATENT	DOCUMENTS		
_		Foreign Patent Document			Pages, Cohumns, Lines,	
Examiner Cite Initials* No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
INVA		WO 97/38723	10/23/97	Immusol Incorporated	\	
MM		WO 98/07865	02/26/98	Genvec, Inc.		_
WW		WO 98/11221	03/19/98	Dana-Farber Cancer Institute		
MM		WO 98/13499	04/02/98	The Scripps Research Institute		
WW		WO 98/22609	05/28/98	Genzyme Corporation		
MW		WO 98/ 32842	07/30/98	Genetic Therapy, Inc.		

Examiner Signature	Myhanich	Date Considered	5/10/08

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute 1	for form 1449A/PTO				Complete if Known	
INFO	RMATION	DI	SCLOSURE	Application Number	09/348,354	
STATEMENT BY APPLICANT		Filling Date	July 7, 1999			
V 2122				First Named Inventor	Havenga et al.	
				Group Art Unit	1636	
(use as many sheets as necessary)			necessary)	Examiner Name	M. Marvich	
Sheet	٥	of	22	Attorney Docket Number	2578-4123 2115	

		`	U.S. PATENT D	OCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Initials *	No.1	Number - Kind Code ² (if known)	MDA-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	1	 			
		 			
	<u> </u>		 		
	ļ		_		
	<u> </u>		ļ		
	╂	_	 		· · · · · · · · · · · · · · · · · · ·
	 		<u> </u>		
	<u> </u>	<u> </u>			
			<u> </u>		
	<u> </u>				
	├				
	ļ		 		
	 				· · · · · · · · · · · · · · · · · · ·
	1				

		FOR	EIGN PATEN	T DOCUMENTS		
		Foreign Patent Document			Pages, Cohmus, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Ched Document	Where Relevant Passages or Relevant ∧ Figures Appear	T ⁶
MW		WO 98/40509	09/17/98	Genvec, Inc.		<u> </u>
MW		WO 98/49300	11/05/98	Collateral Theraputics		
MM		WO 98/50053 A1	11/12/98	Genetic Therapy, Inc.		
MM		EP 1016726	12/30/98	introgene B.V.		
MW		WO 99/32647	07/01/99	Introgene B.V.		
MM		EP 1067188	07/08/99	Introgene B.V.		

Examiner Signature M	ich	Date Considered	5716/08

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 09/348,354 INFORMATION DISCLOSURE **Application Number** July 7, 1999 STATEMENT BY APPLICANT First Named Inventor Havenga et al. Group Art Unit 1636 (use as many sheets as necessary) M. Marvich **Examiner Name** 2578-4123.2US

Attorney Docket Number

U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant			
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear			
,		·						
								
				-				

		FOR	EIGN PATEN	T DOCUMENTS		
		Foreign Patent Document			Pages, Columns, Lines,	
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages of Relevant Figures Appear	76
MW		WO 99/47180A1	09/23/99	Genzyme Corporation		
WWA		WO 99/55132 .	11/04/99	Introgene B.V.		/
MANA		WO 99/58646	11/18/99	Genera S.P.A.		
mm		EP 1020529	11/19/99	Introgene B.V.		
ww		WO 00/03029	01/20/00	Introgene B.V.		
MM		WO 00/24730 A2 -	05/04/00	The University of British Columbia	6	

Signature Considered 5/10/05	Examiner Signature	MVlani	<i>L</i> 1	
------------------------------	-----------------------	--------	------------	--

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Preperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known
INFORMATION DISCLOSURE	Application Number	09/348,354
STATEMENT BY APPLICANT	Filing Date	July 7, 1999
	First Named Inventor	Havenga et al.
	Group Art Unit	1636
(use as many sheets as necessary)	Examiner Name	M. Marvich

Attorney Docket Number

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant		
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear		
	 		 				
	 		 				
	 						
	ļ						
	 						
	 		•				
-	 						
	 		-				
			1	-			
	I						
	 	·			····		
	 						
	 						
	 						

		FOR	EIGN PATEN	T DOCUMENTS			
		Foreign Patent Document			Pages, Columns, Lines,		
Examiner Initials*	Cite No. ¹	Country Cride ³ - Number ⁴ - Kind Code ⁵ (if Intown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Re Passages or Figures /	Relevant	T⁵
MMV		WO 00/31285	06/02/00	Introgene B.V.			•
ЙŴ		WO 00/52186	09/08/00	Introgene B.V.			
MM		WO 00/70071 A1	11/23/00	Introgene B.V.			
Mus		WO 01/04334	01/18/01	Introgene B.V.			
MM'		WO 01/90158 A1	11/29/01	Crucell Holland B.V.			
WW		WO 02/24730	03/28/02	Crucell Holland B.V.			
MAMA		WO 02/27006	04/04/02	Crucell Holland B.V.			

Examiner Signature	M Yhmani Ch	Date Considered	5/10/05
	· V\		07 V- LOG

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Emer Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 09/348,354 INFORMATION DISCLOSURE Filing Date July 7, 1999 STATEMENT BY APPLICANT First Named Inventor Havenga et al. **Group Art Unit** 1636 (use as many sheets as necessary) M. Marvich Examiner Name Sheet 2578-4123 2US Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MM		ABRAHAMSEN et al., "Construction of an Adenovirus Type 7a E1A" Vector," JOURNAL OF VIROLOGY, NOV. 1997, P. 8946-8951 Vol. 71, No. 11.	
MM		ALBIGES-RIZO et al., "Human Adenovirus Serotype 3 Fiber Protein," Journal of Biological Chemistry, 266(6), 3961-3967 (1991).	
MM		ANDERSON, Nature, "Human gene therapy," Apr. 1998, Vol. 392, pp. 25-30.	
MM		ATHAPPILLY et al., "The Refined Crystal Structure of Hexon, the Major Coat Protein of Adenovirus Type 2, at 2+9 A Resolution," J. Mol. Biol. (1994) 242, 430-455.	
MM		BAI et al., "Mutations That After an Arg-Gly-Asp (RGD) Sequence in the Adenovirus Type 2 Penton Base Protein Abolish Its Cell-Rounding Activity and Delay Virus Reproduction in Flat Cells," Journal of Virology, 67(9), 5198-5205 (1993).	
Mrw		BAILEY et al., "Phylogenetic Relationships among Adenovirus Serotypes," Virology, 205, 439-452 (1994).	
MM		BALL-GOODRICH et al., "Parvoviral Target Cell Specificity: Acquisition of Fibrotropism by a Mutant of the Lymphotropic Strain of Minute Virus of Mice Involves Multiple Amino Acid Substitutions within the Capsid," Virology, 184, 175-186 (1991).	
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	-	BASLER et al., Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35, 1996, Gene 170:249-254.	
MVIV		BASLER et al., "Subgroup B Adenovirus Type 35 Early Region 3 mRNAs Differ from Those of the Subgroup C Adenoviruses," VIROLOGY 215, 165-177 (1996).	
1771M	,	BATRA et al., "Receptor-mediated gene delivery employing lectin-binding specificity," Gene Therapy, 1, 255-260 (1994).	
MW		BERENDSEN, Herman J.C., A Glimpse of the Holy Grail, Science, 1998, Vol. 282, pp. 642-43.	

~^ A		
$\sum I_{i} Y_{i} Y_$	Date	
1/18 N 11/04 A 2/21/	1	711
	Considered	\vdash $I \cap D \cap U \cup U$
	M. Marich	5 1 V \ // // // // // // // // // // // // /



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTO	,	•		Complete if Known
				Application Number	09/348,354
			SCLOSURE	Filing Date	July 7, 1999
STA	TEMENT I	BY A	PPLICANT	First Named Inventor	Havenga et al.
				Group Art Unit	1636
	(use as many s	heets as	necessary)	Examiner Name	M. Marvich
Sheer	13	of	22	Attorney Docket Number	2578-4123 2119

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
KAMA	,	BOURSNELL et al., "In vitro construction of a recombinant adenovirus Ad2:Ad5," Gene, 13, 311-317 (1981).	
MM		BRIDGE et al., "Adenovirus Early Region 4 and Viral DNA Synthesis," Virology 193, 794-801 (1993).	
MM	٦.	BRODY et al., "Adenovirus-Mediated in Vivo Gene Transfer," Annals New York Academy of Sciences pp.90-100.	
MM		CAILLET-BOUDIN et al., "Functional and Structural Effects of an Ala to Val Mutation in the Adenovirus Serotype 2 Fibre," J. Mol. Biol., 217, 477-486 (1991).	
MM		CHIU et al., Folding & Design, "Optimizing energy potentials for success in protein tertiary structure prediction," May 1998, 3:223-228.	
WW		CHROBOCZEK et al., "The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with the Genome of Adenovirus Type 2," Virology, 186, 280-285 (1992).	
MM	٠.	CHROBOCZEK et al., Adenovirus Fiber, Current Topics in Microbiology and Immunology 1995;199 (Pt 1) pp. 163-200.	
MM		CHU et al., "Cell targeting with retroviral vector particles containing antibodyBenvelope fusion proteins," Gene Therapy, 1, 292-299 (1994).	
MM	-	COTTEN et al., "TransferrinBpolycation-mediated introduction of DNA into human leukemic cells: Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels," Proc. Natl. Acad. Sci. USA, 87, 4033-4037 (1990).	
MVM		COTTEN et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," Proc. Natl. Acad. Sci. USA, 89, 6094-6098 (1992).	
MM	:	CRAWFORD-MIKSZA et al., "Adenovirus Serotype Evolution is Driven by Illegitimate Recombination in the Hypervariable Regions of the Hexon Protein," Virology, 224, 357-367 (1996).	

Examiner Signature WMMM (1)	Date Considered	5/10/05
-----------------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 09/348,354 INFORMATION DISCLOSURE July 7, 1999 Filing Date STATEMENT BY APPLICANT Havenga et al. First Named Inventor 1636 Group Art Unit (use as many sheets as necessary) **Examiner Name** M. Marvich Attorney Docket Number 2578-4123 2US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
WW		CRAWFORD-MIKSZA et al., "Analysis of 15 Adenovirus Hexon Proteins Reveals the Location and Structure of Seven Hypervariable Regions Containing Serotype-Specific Residues," Journal of Virology, Mar. 1996, p. 1836-1844.	
WW	:	CROMPTON et al., "Expression of a foreign epitope on the surface of the adenovirus bexon," J. Gen. Virol., 75(1), 133-139 (1994).	
WW		CRYSTAL, Ronald G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," Science, 270, 404-410 (1995).	
MM)		CURIEL et al., "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNABPolylysine Complexes," Human Gene Therapy, 3, 147-154 (1992).	
mm		CURIEL et al., "Adenovirus enhancement of transferrinBpolylysine-mediated gene delivery," Proc. Natl. Acad. Sci. USA, 88, 8850-8854 (1991).	
MM		DE JONG et al., "Adenovirus Isolates From Urine of Patients with Acquired Immunodeficiency Syndrome," The Lancet, June 11, 1983 pp. 1293-1296.	
MM		DE JONG et al., Adenoviruses from Human Immunodeficiency Virus-Infected Individuals, Including Two Strains That Represent New Candidate Serotypes Ad50 and Ad51 of Species B1 and D, Respectively, Journal of Clinical Microbiology, Dec. 1999, p. 3940-45, Vol. 37, No. 12, American Society for Microbiology.	
MM	,	DEFER et al., "Human Adenovirus-Host Cell Interactions: Comparative Study with Members of Subgroups B and C," Journal of Virology, 64(8), 3661-3673 (1990).	
WW		DEONARAIN, "Ligand-targeted receptor-mediated vectors for gene delivery," (1998) Expert Opin. Ther. Pat. 8: 53-69.	
WW		DUKEMA et al., "Transformation of Primary Rat Kidney Cells by DNA Fragments of Weakly Oncogenic Adenoviruses," Journal of Virology, Dec. 1979, p. 943-950.	
MM		DOUGLAS J T et al.: "Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors" Neuromusclar Disorders, Pergamon Press, GB, vol. 7, July 1997 (1997-07), pages 284-298, XP002079944 ISSN: 0960-8966.	

Examiner	MYMourich	Date	C7. 1
Signature	Milman	Considered	3/10/08

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 09/348,354 INFORMATION DISCLOSURE Filing Date July 7, 1999 STATEMENT BY APPLICANT First Named Inventor Havenga et al. Group Art Unit 1636 (use as many sheets as necessary) M. Marvich **Examiner Name** 2578-4123 2US Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
MM	,	DUPUIT et al., "Regenerating Cells in Human Airway Surface Epithelium Represent Preferential Targets for Recombinant Adenovirus," Human Gene Therapy, 6, 1185-1193 (1995).	
MM		ECK et al., "Gene-Based Therapy," (1996) Goodman & Gillman's The Pharmacological Basis of Therapeutics, Mc-Graw-Hill, New York, N.Y., pp. 77-101.	
WW	,	ETIENNE-JULAN et al., "The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cellBvirus linker," Journal of General Virology, 73, 3251-3255 (1992).	
MM		FALGOUT et al., "Characterization of Adenovirus Particles Made by Deletion Mutants Lacking the Fiber Gene," Journal of Virology, 62(2), 622-625 (1988).	
WM		FLOMENBERG et al., "Molecular Epidemiology of Adenovirus Type 35 Infections in Immunocompromised Hosts," The Journal Of Infectious Diseases Vol. 155, No. 6, June 1987.	
WW		FRANCKI et al., "Classification and Nomenclature of Viruses," Fifth Report of the International Committee on Taxonomy of Viruses; Virology Division of the International Union of Microbiology Societies pp. 140-143.	
WW		GALL et al., "Construction and characterization of Hexon-Chimeric Adenoviruses: Specification of adenovirus scrotype," 72(12) Journal of Virology 10260-64 (1998).	
WW		GALL et al., "Adenovirus Type 5 and 7 Capsid Chimera: Fiber Replacement Alters Receptor Tropism without Affecting Primary Immune Neutralization Epitopes," Journal Of Virology, Apr. 1996, p. 2116-2123.	
WW		GEORGE et al., "Gene therapy progress and prospects: adenoviral vectors," Gene Therapy (2003) 10, 1135-1141.	
MM		GORECKI, "Prospects and problems of gene therapy: an update," (2001) Expert Opin. Emerging Drugs 6(2): 187-98.	
WW	/	GREBER et al., "Stepwise Dismantling of Adenovirus 2 during Entry into Cells," Cell, 75, 477-486 (1993).	

					$\overline{}$
Examiner Signature	$\mathcal{M}_{\lambda}\mathcal{N}$	duich	Date Considered	5/10/05	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known 09/348,354 **Application Number** INFORMATION DISCLOSURE Filing Date July 7, 1999 STATEMENT BY APPLICANT First Named Inventor Havenga et al. Group Art Unit 1636 (use as many sheets as necessary) M. Marvich **Examiner Name** 2578-4123 2US Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Ann		GREEN et al., "Evidence for a repeating cross- sheet structure in the adenovirus fibre," EMBO Journal, 2(8), 1357-1365 (1983).	
Min		GRUBB et al., Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans, Nature, 371, 802-806 (1994).	
ww		GURUNATHAN et al., American Association of Immunologists, "CD40 Ligand/Trimer DNA Enhances Both Humoral and Cellular Immune Responses and Indicates Protective Immunity to Infectious and Tumor Challenge," 1998, 161:4563-4571.	
WW	-	HAN et al., "Ligand-directed retroviral targeting of human breast cancer cells," Proc. Natl. Acad. Sci. USA, 92, 9747-9751 (1995).	
MM		HE et al., "A simplified system for generating recombinant adenoviruses," Proc. Natl. Acad. Sci. USA Vol. 95, pp. 2509-2514, March 1998.	
MM		HENRY et al., "Characterization of the Knob Domain of the Adenovirus Type 5 Fiber Protein Expressed in Escherichia coli," Journal of Virology, 68(8), 5239-5246 (1994).	
(MM)		HIDAKA, CHISA, et al., "CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts," 103(4) The Journal of Clinical Investigation 579-87 (February 1999).	
MW		HIERHOLZER et al., "Adenoviruses from Patients with AIDS: A Plethora of Serotypes and A Description of Five New Serotypes of Subgenus D (Types 43-47)," The Journal Of Infectious Diseases Vol. 158, No. 4 October 1988.	
Www		HONG et al., "The Amino Terminus of the Adenovirus Fiber Protein Encodes the Nuclear Localization Signal," Virology, 185(2), 758-767 (1991).	
WM		HORVATH et al., "Nonpermissivity of Human Peripheral Blood Lymphocytes to Adenovirus Type 2 Infection," Journal of Virology, 62(1), 341-345 (1988).	
WW		HUANG et al., "Upregulation of Integrins γ3 and γ5 on Human Monocytes and T Lymphocytes Facilitates Adenovirus- Mediated Gene Delivery," Journal of Virology, 69(4), 2257-2263 (1995).	

Examiner	M Man	Date	Chilia
Signature	VI Yram Ch	Considered	5/10/05

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 09/348,354 INFORMATION DISCLOSURE Filing Date July 7, 1999 STATEMENT BY APPLICANT First Named Inventor Havenga et al. 1636 Group Art Unit (use as many sheets as necessary) **Examiner Name** M. Marvich 2578-4123 2US Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
hill	:	IMLER et al., "Novel complementation cell lines derived from human hung carcinoma A549 cells support the growth of E1- deleted adenovirus vectors," Gene Therapy, Vol. 3: p. 75-84, 1996.	
MV.		JOLLY; viral vector systems for gene therapy, 1994, Cancer Gene Therapy, vol. 1, No. 1: 51-64.	
MM		KANG et al., "Molecular Cloming And Physical Mapping Of The Daa Of Human Adenovirus Type 35," Acta Microbiologica Hungarica 36 (1), pp. 67-75 (1989).	
MM		KANG et al., "Relationship Of E1 And E3 Regions Of Human Adenovirus 35 To Those Of Human Adenovirus Subgroups A, C And D," Acta Microbiologica Hungarica 36 (4), pp. 445-457 (1989).	
WW		KARAYAN et al., "Oligomerization of Recombinant Penton Base of Adenovirus Type 2 and Its Assembly with Fiber in Baculovirus-Infected Cells," Virology, 202, 782-795 (1994).	
MM		KASS-EISLER et al., "Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo," Proc. Natl. Acad. Sci. USA, 90, 11498-11502 (1993).	
MW		KMIEC, "Gene Therapy," American Scientist, Vol. 87, pp.240	
MM		KOMORIYA et al., "The Minimal Essential Sequence for a Major Cell Type-specific Adhesion Site (CS1) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronectin Is Leucine-Aspartic Acid-Valine,: Journal of Biological Chemistry, 266(23), 15075-15079 (1991).	
MM		KRASNYKH et al.: "Generation Of Recombinant Adenovirus Vectors With Modified Fibers For Altering Viral Tropism" Journal Of Virology, The American Society For Microbiology, US, vol. 70, no. 10, 1 October 1996 (1996-10-01), pages 6839-6846, XP002067518 ISSN: 0022-538X.	
MM		LATTANZI, LAURA, et al., "High Efficiency Myogenic Conversion of Human Fibroblasts by Adenoviral Vector-mediated MyoD Gene Transfer," 101(10) J. Clin. Invest. 2119-28 (May 1998).	
mm		LEE et al., "The constitutive expression of the immunomodulatory gp 19k protein in E1', E3' adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector," Gene Therapy (1995) 2, 256-262.	
MM		LEVRERO et al., "Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo," Gene, 101 (1991) 195-202.	

Examiner Signature	Myouid	Date Considered	5/10/05	
-----------------------	--------	--------------------	---------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademer's Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known 09/348,354 Application Number INFORMATION DISCLOSURE July 7, 1999 Filing Date STATEMENT BY APPLICANT First Named Inventor Havenga et al. Group Art Unit 1636 (use as many sheets as necessary) M. Marvich **Examiner Name** Sheet 2578-4123 2US Attorney Ducket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MM		LI et al., "Genetic Relationship between Thirteen Genome Types of Adenovirus 11, 34, and 35 with Different Tropisms," Intervirology 1991;32:338-350.	
MM		LIU et al., Molecular Basis of the inflammatory response to adenovirus vectors. Gene Therapy (2003 10, 935-40.	
MM		MARAVEYAS et al., "Targeted Immunotherapy B An update with special emphasis on ovarian cancer," Acta Oncologica, 32(7/8), 741-746 (1993).	
Mm		MASTRANGELI et al., "ASero-Switch@ Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype," Human Gene Therapy, 7, 79-87 (1996).	
MM		MATHIAS et al., "Multiple Adenovirus Serotypes Use v Integrins for Infection," Journal of Virology, 68(10), 6811-6814 (1994).	
Mus		MAUTNER et al., "Recombination in Adenovirus: DNA Sequence Analysis of Crossover Sites in Intertypic Recombinants," Virology, 131, 1-10 (1983).	
MM		MAUTNER et al., "Recombination in Adenovirus: Analysis of Crossover Sites in Intertypic Overlap Recombinants," Virology, 139, 43-52, (1984).	
WW		Merriam-Webster Dictionary (on line) retrieved from the internet <url:htpp: "derive,"="" 2002.<="" cgi-bin="" dictionary,="" td="" www.m-w.com=""><td></td></url:htpp:>	
Nun		MICHAEL et al., "Addition of a short peptide ligand to the adenovirus fiber protein," Gene Therapy, 2, 660-668 (1995).	
hun		MICHAEL et al., "Binding-incompetent Adenovirus Facilitates Molecular Conjugate-mediated Gene Transfer by the Receptor-mediated Endocytosis Pathway," Journal of Biological Chemistry, 268(10), 6866-6869 (1993).	
WM		MILLER et al., "Targeted vectors for gene therapy," FASEB Journal, 9, 190-199 (1995).	

	Examiner Signature	M. Marich	Date Considered	5/10/05
--	-----------------------	-----------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 09/348,354 INFORMATION DISCLOSURE July 7, 1999 Filing Date STATEMENT BY APPLICANT First Named Inventor Havenga et al. Group Art Unit 1636 (use as many sheets as necessary) M. Marvich Examiner Name Sheet Attorney Docket Number 2578-4123 2US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Mm		NEDA et al., "Chemical Modification of an Ecotropic Murine Leukemia Virus Results in Redirection of Its Target Cell Specificity," Journal of Biological Chemistry, 266(22), 14143-14146 (1991).	
MWV		NEMEROW et al., "The Role of v Integrins in Adenovirus Infection," Biology of Vitronectins and their Receptors, 177-184 (1993).	
WW		NEMEROW et al., "Adenovirus entry into host cells: a role for , integrins," Trends In Cell Biology, 4, 52-55 (1994).	
WW		NGO et al., The Protein Folding Problem and Tertiary Structure Prediction, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," 1994, Merz et al. (Editors), Birkhauser, Boston, MA, pp. 433 and 492-495.	
MNA		NOVELLI et al., "Deletion Analysis of Functional Domains in Baculovirus-Expressed Adenovirus Type 2 Fiber," Virology, 185, 365-376 (1991).	
MW		ORKIN et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," (1995), http://www.nih.gov/news/panelrep.html	
MM		PETERANDERL et al., "Trimerization of the Heat Shock Transcription Factor by a Triple-Stranded -Helical Coiled-Coil," Biochemistry, 31, 12272-12276 (1992).	
MM		PRINCE, "Gene Transfer: A Review Of Methods And Applications," Pathology (1998), 30, pp. 335-347.	
MM		PRING-ÅKERBLOM et al., "Sequence Characterization and Comparison of Human Adenovirus Subgenus B and E Hexons," Virology, 212, 232-36 (1995).	
MM	-	RAGOT et al.,: "Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice" Nature, Macmillan-Journals-Etd. London, GB, vol. 361, no. 6413, 1993, pages 647-650, XP002162515 ISSN: 0028-0836.	
MM		REA et al., "Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells." Journal Of Immunology, (2000 APR 15) 166 (8) 5236-44., - 15 April 2001 (2001-04-15) XP002192775.	

		7	
Examiner	M Marsich	Date	5/10/08
Signature	VN VROUNCE	Considered	3110108

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is anached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

	Substitute fo	r form 1449A/PTO		-		Complete if Known
	TA IDO				Application Number	09/348,354
				SCLOSURE	Filing Date	July 7, 1999
	STAT	EMENT B	Y A	PPLICANT	First Named Inventor	Havenga et al.
					Group Art Unit	1636
		(use as many sh	eeis as	necessary)	Examiner Name	M. Marvich
く	Sheet	20	of	22	Attorney Docket Number	2578-4123 2US

	T	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MM		ROBBINS et al., "Viral Vectors for Gene Therapy," Pharmacol. Ther. Vol. 80, No. 1, pp. 35-47, 1998.	
(ROBERTS et al., "Three-Dimensional Structure of the Adenovirus Major Coat Protein Hexon," Science, 232, 1148-51 (1986).	
		ROELVINK et al., "The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F, Journal Of Virology, Oct. 1998, P. 7909-7915, Vol. 72, No. 10.	
		ROMANO, "Gene Transfer in Experimental Medicine," Drug & News Perspectives, Vol. 16, No. 5, 2003, 13 pages.	
	-	RUSSELL et al., "Retroviral vectors displaying functional antibody fragments," Nucleic Acids Research, 21(5), 1081-1085 (1993).	
		RUSSELL, "Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and Prospects," European Journal of Cancer, Vol. 30A, No. 8, pp. 1165	
		SABOURIN et al., "The molecular regulation of myogenesis," (2000) Clin.' Genet. 57(1): 16-25.	
		SCHNURR et al., "Two New Candidate Adenovirus Serotypes," Intervirology 1993;36:79-83.	
		SCHULICK et al., "Established Immunity Precludes Adenovirus-mediated Gene Transfer in Rat Carotid Arteries," The Journal of Clinical Investigation Volume 99, Number 2, January 1997, 209-219.	· -
		SEGERMAN et al.: "Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines" Journal of Virology, The American Society for Microbiology, US, vol. 74, no. 3, February 2000 (200-02), pages 1457-1467, XP002161682 ISSN: 0022-538X.	
		SHAYAKHMETOV et al., "Efficient Gene Transfer into Human CD34" Cells by a Retargeted Adenovirus Vector," Journal Of Virology, Mar. 2000, p. 2567-2583.	
		SIGNAS et al., "Adenovirus 3 Fiber Polypeptide Gene: Implications for the Structure of the Fiber Protein," Journal of Virology, 53(2), 672-678 (1985).	
MM	•	SILVER et al., "Interaction of Human Adenovirus Serotype 2 with Human Lymphoid Cells," Virology, 165, 377-387 (1988).	

Examiner Signature	Myhanich	Date Considered	5/10/05
_			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 09/348,354 INFORMATION DISCLOSURE July 7, 1999 Filing Date STATEMENT BY APPLICANT First Named Inventor Havenga et al. 1636 Group Art Unit (use as many sheets as necessary) M. Marvich **Examiner Name** 2578-4123 2US Attorney Docket Number

]		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MM		STEVENSON et al.; Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein, 1997, Journal of Virology, Vol. 71: 4782-4790.	
(STEWART et al., "Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy," EMBO Journal, 12(7), 2589-2599 (1993).	
		STRATFORD-PERRICAUDET LD et al.: "Widespread Long-Term Gene Transfer To Mouse Skeletal Muscles And Heart" Journal Of Clinical Investigation, New York, NY, US, vol. 90 no. 2, August 1992 (1992-08), ISSN: 0021-9738.	
		TOOGOOD et al., "The Adenovirus Type 40 Hexon: Sequence, Predicated Structure and Relationship to Other Adenovirus Hexons," J. gen. Virol (1989), 70, 3203-3214.	
		VALDERRAMA-LEON et al., "Restriction Endomuclease Mapping of Adenovirus 35, a Type Isolated from Immunocompromised Hosts," Journal Of Virology, Nov. 1985, p. 647-650.	
		VERMA et al., Nature, "Gene therapy-promises, problems and prospects," Sep. 1997, Vol. 389, pp. 239-242.	
1		WADELL, "Molecular Epidemiology of Human Adenoviruses," Microbiology and Immunology, Vol. 110 pp.191-220.	
		WAGNER et al., "Coupling of adenovirus to transferrinBpolylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes," Proc. Natl. Acad. Sci. USA, 89, 6099-6103 (1992).	
		WATSON et al., "An Antigenic Analysis of the Adenovirus Type 2 Fibre Polypeptide," Journal of Virology, 69, 525-535 (1988).	
		WICKHAM et al., "Integrins 22 and 22 Promote Adenovirus Internalization but Not Virus Attachment," Cell, 73, 309-319 (1993).	
my		WICKHAM et al., "Integrin v5 Selectively Promotes Adenovirus Mediated Cell Membrane Permeabilization," Journal of Cell Biology, 127(1), 257-264 (1994).	

	Examiner Signature	M Marrich	Date Considered	5 lo los
--	-----------------------	-----------	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

2578-4123 2US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 09/348,354 INFORMATION DISCLOSURE Filing Date July 7, 1999 STATEMENT BY APPLICANT Havenga et al. First Named Inventor Group Art Unit 1636 (use as many sheets as necessary) **Examiner Name** M. Marvich

Attorney Docket Number

ij

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
MM		WICKHAM et al.: "Increased In Viro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins," Journal of Virology, Nov. 1997, p. 8221-8229.		
mm		ZHONG et al.: "Recombinant Advenovirus Is An Efficient And Non-Pertubing Genetic Vector For Human Dendritic Cells" European Journal Of Immunology, Weinheim, DE, vol. 29, no. 3, 1999, pages 964-972, XP000938797 ISSN: 0014-2980.		

Examiner Signature March Date Considered 5/10/05		I // V
--	--	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.